

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change
NEWS 22 DEC 17 USPATOLD added to additional database clusters
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27 DEC 17 CA/CAplus enhanced with new custom IPC display formats
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available
NEWS 30 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances

10 / 513699

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:01:03 ON 18 JAN 2008

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 18 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9
DICTIONARY FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9

New CAS Information Use Policies, enter HELP USAGE TERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10596851.str



chain nodes :

19 20 21 22 23 24 25 26 27 28 29 30 31 32 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

3-21 6-31 8-31 12-27 13-34 16-31 19-22 19-20 20-21 20-24 21-32 23-24

25-26 26-27 26-29 27-30 28-29

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18

14-15 15-16 16-17 17-18

exact/norm bonds :

12-27 13-14 13-18 13-34 14-15 15-16 16-17 16-31 17-18 19-20 20-21 20-24

21-32 25-26 26-27 26-29 27-30 28-29

exact bonds :

3-21 6-31 8-31 19-22 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 : 13 :

G1:Cb,Ak

G2:H,Cb,Ak

Match level :

| | | | | | | | | | |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|---------|
| 1:Atom | 2:Atom | 3:Atom | 4:Atom | 5:Atom | 6:Atom | 7:Atom | 8:Atom | 9:Atom | 10:Atom |
| 11:Atom | 12:Atom | 13:Atom | 14:Atom | 15:Atom | 16:Atom | 17:Atom | 18:Atom | 19:CLASS | |
| 20:CLASS | 21:CLASS | 22:CLASS | 23:CLASS | 24:CLASS | 25:CLASS | 26:CLASS | 27:CLASS | | |
| 28:CLASS | 29:CLASS | 30:CLASS | 31:CLASS | 32:CLASS | 34:CLASS | | | | |

10/513699

L1 STRUCTURE UPLOADED

=> s 11 full
FULL SEARCH INITIATED 15:02:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 203 TO ITERATE

100.0% PROCESSED 203 ITERATIONS 90 ANSWERS
SEARCH TIME: 00.00.01

L2 90 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
178.82 179.03

FILE 'CAPLUS' ENTERED AT 15:02:19 ON 18 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 17 Jan 2008 (20080117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12 full
L3 2 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:638860 CAPLUS
 DOCUMENT NUMBER: 143:153402
 TITLE: Preparation of diarylmethylpiperazines as δ receptor ligands for the treatment of pain
 INVENTOR(S): Brown, William; Griffin, Andrew
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| WO 2005066148 | A1 | 20050721 | WO 2005-SE14 | 20050105 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| AU 2005204010 | A1 | 20050721 | AU 2005-204010 | 20050105 |
| CA 2552851 | A1 | 20050721 | CA 2005-2552851 | 20050105 |
| EP 1706393 | A1 | 20061004 | EP 2005-704688 | 20050105 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS | | | | |
| CN 1926122 | A | 20070307 | CN 2005-80006254 | 20050105 |
| BR 2005006702 | A | 20070502 | BR 2005-6702 | 20050105 |
| JP 2007517873 | T | 20070705 | JP 2006-549190 | 20050105 |
| IN 2006DN03738 | A | 20070420 | IN 2006-DN3738 | 20060629 |
| MX 2006PA07664 | A | 20060904 | MX 2006-PA7664 | 20060703 |
| NO 2006003619 | A | 20061009 | NO 2006-3619 | 20060809 |
| US 2007293502 | A1 | 20071220 | US 2007-596851 | 20070529 |
| PRIORITY APPLN. INFO.: | | | SE 2004-27 | A 20040109 |
| | | | WO 2005-SE14 | W 20050105 |

OTHER SOURCE(S): CASREACT 143:153402; MARPAT 143:153402
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = alkyl, cycloalkyl] and their pharmaceutically acceptable salts were prepared. For example, N-alkylation of piperazine II (R1 =H) with bromoethyl Me ether afforded the hCL salt of claimed diarylmethylpiperazine II (R1 = CH2CH2OCH3) in 68% yield. In human δ receptor assays, certain examples of compds. I exhibited IC50 values ranging from 0.2-3.7 nM, with an average of 1 nM (sic).

IT 859634-99-4P 859635-00-0P 859635-01-1P
 859635-02-2P 859635-03-3P 859635-04-4P
 859635-05-5P 859635-06-6P 859635-07-7P
 859635-08-8P 859635-09-9P 859635-10-2P
 859635-11-3P 859635-12-4P 859635-13-5P
 859635-14-6P 859635-15-7P 859635-16-8P
 859635-17-9P 859635-18-0P 859843-90-6P
 859843-91-7P 859843-92-8P 859843-93-9P
 859843-94-0P 859843-95-1P 859843-96-2P
 859843-97-3P 859843-98-4P 859843-99-5P
 859844-00-1P 859844-01-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylmethylpiperazines as δ receptor ligands for treatment of pain)

RN 859634-99-4 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 859635-00-0 CAPLUS

CN Carbamic acid, [3-[(S)-(4-butyl-1-piperazinyl)[4-(diethylamino)carbonyl]phenyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 859635-01-1 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 859635-02-2 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 859635-03-3 CAPLUS

CN Carbamic acid, [3-[(S)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 859635-04-4 CAPLUS

CN Carbamic acid, [3-[(S)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 859635-05-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-06-6 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-ethoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859635-07-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-methoxypropyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-08-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-09-9 CAPLUS

CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-10-2 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-11-3 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-12-4 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-13-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-14-6 CAPLUS

CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-15-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-16-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 859635-17-9 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-ethyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859635-18-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859843-90-6 CAPLUS

CN Carbamic acid, [3-[(S)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 859843-91-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 859843-92-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-93-9 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

10/513699

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-94-0 CAPLUS

CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-95-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-96-2 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-97-3 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/513699




● HCl

RN 859843-98-4 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-99-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/513699




● HCl

RN 859844-00-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859844-01-2 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl


IT 859635-21-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylmethylpiperazines as δ receptor ligands for treatment of pain)

RN 859635-21-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(S)-[4-[(diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:412932 CAPLUS
 DOCUMENT NUMBER: 140:423709
 TITLE: Preparation of N-[4-(phenylpiperazinylmethyl)phenyl]carbamates for treatment of pain, anxiety, or gastrointestinal disorders
 INVENTOR(S): Brown, William; Griffin, Andrew; Jones, Paul; Page, Daniel; Plobeck, Niklas; Walpole, Christopher
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|-------------|
| WO 2004041802 | A1 | 20040521 | WO 2003-SE1707 | 20031105 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2502732 | A1 | 20040521 | CA 2003-2502732 | 20031105 |
| AU 2003278665 | A1 | 20040607 | AU 2003-278665 | 20031105 |
| EP 1562924 | A1 | 20050817 | EP 2003-770198 | 20031105 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003015995 | A | 20050927 | BR 2003-15995 | 20031105 |
| CN 1711252 | A | 20051221 | CN 2003-80102831 | 20031105 |
| JP 2006514002 | T | 20060427 | JP 2004-549776 | 20031105 |
| NZ 539484 | A | 20070531 | NZ 2003-539484 | 20031105 |
| IN 2005DN01579 | A | 20061229 | IN 2005-DN1579 | 20050419 |
| MX 2005PA04708 | A | 20050803 | MX 2005-PA4708 | 20050502 |
| US 2006122193 | A1 | 20060608 | US 2005-533654 | 20050504 |
| US 7253173 | B2 | 20070807 | | |
| ZA 2005003556 | A | 20060830 | ZA 2005-3556 | 20050504 |
| NO 2005002698 | A | 20050606 | NO 2005-2698 | 20050606 |
| US 2007254890 | A1 | 20071101 | US 2007-774935 | 20070709 |
| PRIORITY APPLN. INFO.: | | | SE 2002-3303 | A 20021107 |
| | | | WO 2003-SE1707 | W 20031105 |
| | | | US 2005-533654 | A1 20050504 |

OTHER SOURCE(S): MARPAT 140:423709
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted (hetero)aryl(alkyl); R2 and

R3 = independently H or (un)substituted (cyclo)alkyl; or pharmaceutically acceptable salts, diastereomers, enantiomers, or mixts. thereof] were prepared as opioid δ receptor ligands. For example, 4-carboxybenzaldehyde was amidated with diethylamine using SOC12 in CH₂C₁₂ to give N,N-diethyl-4-formylbenzamide (90%). Coupling of the amide with N-Boc-piperazine in the presence of benzotriazole in toluene, followed by reaction with 3-bromophenylzinc iodide in THF, afforded tert-Bu 4-[(3-bromophenyl)[4-[(diethylamino)carbonyl]phenyl]methyl]-1-piperazinecarboxylate (33%). Coupling with Me carbamate (62%) using xantphos, Cs₂CO₃, and Pd₂(dba)₃ in dioxane, deprotection (89%) with TFA in CH₂C₁₂, and chiral HPLC separation of the enantiomers provided (-)-[3-[(4-[(diethylamino)carbonyl]phenyl)-1-piperazinylmethyl]phenyl]carbamic acid Me ester. Reaction of the piperazine with benzaldehyde in the presence of NaBH(OAc)₃ in CH₂C₁₂ gave (R)-II. In binding assays using human 293S cells expressing cloned human opioid receptors and neomycin resistance, (R)-II and ten other exemplified compds. exhibited strong binding to the δ receptor with IC₅₀ values in the range of 0.25-0.74 nM and showed some activity toward the κ (IC₅₀ = 247-1636 nM) and μ (IC₅₀ = 93-1100 nM) receptors. In functional assays, (R)-II demonstrated δ receptor agonist activity by activating the binding of GTP to G-proteins. Thus, I and their pharmaceutical compns. are useful in therapy, in particular for the treatment of gastrointestinal disorders, anxiety, or pain (no data).

IT 691890-43-4P, 4-[(4-[(Diethylamino)carbonyl]phenyl)[3-[(methoxycarbonyl)amino]phenyl]methyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)

RN 691890-43-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(4-[(diethylamino)carbonyl]phenyl)[3-[(methoxycarbonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 691890-67-2P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]


10/513699

]carbamates as δ receptor agonists for treatment of pain,
anxiety, or gastrointestinal disorders)

RN 691890-67-2 CAPLUS

CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 691890-72-9P 691890-74-1P 691890-76-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)

RN 691890-72-9 CAPLUS


CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)

CM 1


CRN 691890-71-8

CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (+).



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 691890-74-1 CAPLUS
 CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-73-0
CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 691890-76-3 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 691890-75-2
CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 691890-51-4P, (R)-Methyl [3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-52-5P,
 (S)-Methyl [3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-53-6P 691890-54-7P
 691890-55-8P 691890-56-9P 691890-57-0P
 691890-58-1P 691890-59-2P 691890-60-5P
 691890-61-6P 691890-62-7P 691890-63-8P
 691890-64-9P 691890-65-0P 691890-66-1P
 691890-68-3P 691890-69-4P 691890-70-7P
 691890-71-8P 691890-73-0P 691890-75-2P
 691890-77-4P, Methyl [3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-78-5P,
 Methyl [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(thien-2-ylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-79-6P,
 Methyl [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(thien-3-ylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-80-9P,
 Methyl [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(2-furylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-81-0P, Methyl
 [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(3-furylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-82-1P, Methyl
 [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(1H-imidazol-2-ylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-83-2P, Methyl
 [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(pyridin-2-ylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-84-3P, Methyl
 [3-[(4-[(diethylamino)carbonyl]phenyl)[4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl]phenyl]carbamate 691890-85-4P, Methyl

[3-[[4-[(diethylamino)carbonyl]phenyl][4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-86-5P 691890-87-6P
 691890-88-7P 691890-89-8P 691890-90-1P
 691890-91-2P 691890-92-3P 691890-93-4P
 691890-94-5P 691890-95-6P 691890-96-7P
 691890-97-8P 691890-98-9P 691890-99-0P
 691891-00-6P 691891-01-7P 691891-02-8P
 691891-03-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)

RN 691890-51-4 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-52-5 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-53-6 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-54-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-55-8 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-56-9 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-57-0 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinylmethylphenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-58-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinylmethylphenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-59-2 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-60-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-61-6 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-62-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-63-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-64-9 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-65-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinylmethylphenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-66-1 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinylmethylphenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-68-3 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-69-4 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-70-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 691890-71-8 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 691890-73-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-75-2 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/513699




RN 691890-77-4 CAPLUS

CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-78-5 CAPLUS


CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-79-6 CAPLUS


10/513699

CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 691890-80-9 CAPLUS

CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanyl methyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 691890-81-0 CAPLUS


CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanyl methyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-82-1 CAPLUS
 CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 691890-83-2 CAPLUS
 CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 691890-84-3 CAPLUS

CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-85-4 CAPLUS

CN Carbamic acid, [3-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-86-5 CAPLUS


CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

10/513699

CM 1


CRN 691890-51-4
CMF C31 H38 N4 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691890-87-6 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI)
(CA INDEX NAME)


CM 1

CRN 691890-52-5
CMF C31 H38 N4 O3

Absolute stereochemistry. Rotation (+).



CM 2


CRN 76-05-1
CMF C2 H F3 O2RN 691890-88-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-53-6
CMF C29 H36 N4 O3 S


Absolute stereochemistry. Rotation (+).

10/513699



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691890-89-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-54-7
CMF C29 H36 N4 O3 S


Absolute stereochemistry. Rotation (-).

10/513699



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691890-90-1 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-55-8
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (+).




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 691890-91-2 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-56-9
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 691890-92-3 CAPLUS
 CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-57-0
CMF C29 H36 N4 O4


Absolute stereochemistry. Rotation (+).

10/513699



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691890-93-4 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-58-1
CMF C29 H36 N4 O4


Absolute stereochemistry. Rotation (-).

10/513699



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691890-94-5 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinylmethyl]phenyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-59-2
CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (+).



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 691890-95-6 CAPLUS
 CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-61-6
CMF C28 H36 N6 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 691890-96-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 691890-62-7
CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 691890-97-8 CAPLUS
 CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1


CRN 691890-63-8
 CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 691890-98-9 CAPLUS
 CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinylmethylphenyl]-, methyl ester, trifluoroacetate (10:19) (9CI) (CA INDEX NAME)

CM 1


CRN 691890-64-9
 CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 691890-99-0 CAPLUS
 CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-65-0
 CMF C30 H37 N5 O3


Absolute stereochemistry. Rotation (-).

10/513699




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691891-00-6 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, hydrochloride (10:29) (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




●29/10 HCl

10/513699

RN 691891-01-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, hydrochloride (2:3) (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 3/2 HCl

RN 691891-02-8 CAPLUS


CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 691890-70-7

CMF C28 H35 N5 O3 S


Absolute stereochemistry. Rotation (-).



10/513699

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691891-03-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanyl)methyl]-1-piperazinyl]methyl]phenyl-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 691890-60-5
CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



10/513699

<12/04/2007>

Erich Leese

10/513699

=> d his

(FILE 'HOME' ENTERED AT 15:01:03 ON 18 JAN 2008)

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 18 JAN 2008

L1 STRUCTURE UPLOADED
L2 90 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:02:19 ON 18 JAN 2008

L3 2 S L2 FULL

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 12.82 | 191.85 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -1.60 | -1.60 |

STN INTERNATIONAL LOGOFF AT 15:04:33 ON 18 JAN 2008